Kamada Ltd (KMDA) FinancialsKMDAKamada Ltd

Kamada Ltd. (KMDA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Proprietary Products, accounting for 80.1% of total sales, equivalent to $36.23M. Another important revenue stream is Distribution. Understanding this composition is critical for investors evaluating how KMDA navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Kamada Ltd. maintains a gross margin of 40.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 17.32%, while the net margin is 16.86%. These profitability ratios, combined with a Return on Equity (ROE) of 8.40%, provide a clear picture of how effectively KMDA converts its operational activities into shareholder value.

In the context of the broader market, KMDA competes directly with industry leaders such as COAG and ABSI. With a market capitalization of $438.60M, it holds a significant position in the sector. When comparing efficiency, KMDA's gross margin of 40.91% stands against COAG's N/A and ABSI's 100.00%. Such benchmarking helps identify whether Kamada Ltd. is trading at a premium or discount relative to its financial performance.

Kamada Ltd. has shown a consistent increase in revenue, with Q2 2026 revenue at $54.92 million, up from $44.72 million in Q2 2025. The gross margin for Q2 2026 is 40.91%, which is slightly lower than previous quarters, indicating some pressure on profitability. However, the net income for Q2 2026 reached $9.26 million, showing strong growth compared to $7.38 million in Q2 2025.